CD146 is a coreceptor for VEGFR-2 in tumor angiogenesis

Blood

Volumn 120, Issue 11, 2012, Pages 2330-2339

  Jiang, Tianxia ^a   Zhuang, Jie ^a   Duan, Hongxia ^a   Luo, Yongting ^a   Zeng, Qiqun ^a   Fan, Kelong ^a   Yan, Huiwen ^a   Lu, Di ^a   Ye, Zhongde ^a   Hao, Junfeng ^a   Feng, Jing ^a   Yang, Dongling ^a   Yan, Xiyun ^a  

^a INSTITUTE OF BIOPHYSICS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CD146 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY AA1; MONOCLONAL ANTIBODY AA98; PROTEIN KINASE B; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ARTICLE; CANCER INHIBITION; CELL MIGRATION; CONTROLLED STUDY; EMBRYO; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT GENE; MELANOMA; MICROVASCULARIZATION; MOUSE; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION; TUMOR ANGIOGENESIS; TUMOR XENOGRAFT;

EID: 84866343239     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-01-406108     Document Type: Article

References (48)

1. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473(7347):298-307.
2. Grothey A, Galanis E. Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol. 2009;6(9):507-518.
3. Tugues S, Koch S, Gualandi L, et al. Vascular endothelial growth factors and receptors: antiangiogenic therapy in the treatment of cancer. Mol Aspects Med. 2011;32(2):88-111.
4. Kaipainen A, Korhonen J, Mustonen T, et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci U S A. 1995;92(8):3566-3570.
5. Potente M, Gerhardt H, Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell. 2011;146(6):873-887.
6. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335-2342. (Pubitemid 38702844)
7. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542- 2550. (Pubitemid 44917502)
8. Yang JC, Haworth,L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349(5):427-434. (Pubitemid 36910021)
9. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357(26):2666-2676.
10. Van Cutsem E, Lambrechts D, Prenen H, et al. Lessons from the adjuvant bevacizumab trial on colon cancer: what next? J Clin Oncol. 2011;29(1):1-4.
11. Lehmann JM, Riethmuller G, Johnson JP. MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. Proc Natl Acad Sci U S A. 1989;86(24):9891-9895. (Pubitemid 20030740)
12. Yan X, Lin Y, Yang D, et al. A novel anti-CD146 monoclonal antibody, AA98, inhibits angiogenesis and tumor growth. Blood. 2003;102(1):184-191. (Pubitemid 36759653)
13. Kang Y, Wang F, Feng J, et al. Knockdown of CD146 reduces the migration and proliferation of human endothelial cells. Cell Res. 2006;16(3):313-318.
14. So JH, Hong SK, Kim HT, et al. Gicerin/Cd146 is involved in zebrafish cardiovascular development and tumor angiogenesis. Genes Cells. 2010;15(11):1099-1110.
15. Bu P, Gao L, Zhuang J, et al. Anti-CD146 monoclonal antibody AA98 inhibits angiogenesis via suppression of nuclear factor-kappaB activation. Mol Cancer Ther. 2006;5(11):2872-2878. (Pubitemid 44849014)
16. Liu Q, Yan X, Li Y, et al. Pre-eclampsia is associated with the failure of melanoma cell adhesion molecule (MCAM/CD146) expression by intermediate trophoblast. Lab Invest. 2004;84(2):221-228. (Pubitemid 41656503)
17. Liu Q, Zhang B, Zhao X, et al. Blockade of adhesion molecule CD146 causes pregnancy failure in mice. J Cell Physiol. 2008;215(3):621-626. (Pubitemid 351632683)
18. Zeng Q, Li W, Lu D, et al. CD146, an epithelial-mesenchymal transition inducer, is associated with triple-negative breast cancer. Proc Natl Acad Sci U S A. 2012;109(4):1127-1132.
19. Ouhtit A, Gaur RL, Abd Elmageed ZY, et al. Towards understanding the mode of action of the multifaceted cell adhesion receptor CD146. Biochim Biophys Acta. 2009;1795(2):130-136.
20. Bu P, Zhuang J, Feng J, et al. Visualization of CD146 dimerization and its regulation in living cells. Biochim Biophys Acta. 2007;1773(4):513-520. (Pubitemid 46441512)
21. Zheng C, Qiu Y, Zeng Q, et al. Endothelial CD146 is required for in vitro tumor-induced angiogenesis: the role of a disulfide bond in signaling and dimerization. Int J Biochem Cell Biol. 2009;41(11):2163-2172.
22. Anfosso F, Bardin N, Frances V, et al. Activation of human endothelial cells via S-endo-1 antigen (CD146) stimulates the tyrosine phosphorylation of focal adhesion kinase p125(FAK). J Biol Chem. 1998;273(41):26852-26856. (Pubitemid 28471703)
23. Anfosso F, Bardin N, Vivier E, et al. Outside-in signaling pathway linked to CD146 engagement in human endothelial cells. J Biol Chem. 2001;276(2):1564-1569. (Pubitemid 32096592)
24. Zhang Y, Zheng C, Zhang J, et al. Generation and characterization of a panel of monoclonal antibodies against distinct epitopes of human CD146. Hybridoma (Larchmt). 2008;27(5):345-352.
25. Luo Y, Zheng C, Zhang J, et al. Recognition of CD146 as an ERM-binding protein offers novel mechanisms for melanoma cell migration. Oncogene. 2012;31(3):306-321.
26. Nagata D, Mogi M, Walsh K. AMP-activated protein kinase (AMPK) signaling in endothelial cells is essential for angiogenesis in response to hypoxic stress. J Biol Chem. 2003;278(33):31000-31006. (Pubitemid 36994613)
27. Redmond EM, Cullen JP, Cahill PA, et al. Endothelial cells inhibit flow-induced smooth muscle cell migration: role of plasminogen activator inhibitor-1. Circulation. 2001;103(4):597-603. (Pubitemid 32116247)
28. Tremmel M, Matzke A, Albrecht I, et al. A CD44v6 peptide reveals a role of CD44 in VEGFR-2 signaling and angiogenesis. Blood. 2009;114(25):5236-5244.
29. Yancopoulos, G.D. Clinical application of therapies targeting VEGF. Cell. 2010;143(1):13-16.
30. Bevacizumab. Anti-VEGF monoclonal antibody, avastin, rhumab-VEGF. Drugs R D. 2002;3(1):28-30.
31. Orian-Rousseau V, Chen L, Sleeman JP, et al. CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev. 2002;16(23):3074-3086. (Pubitemid 35424194)
32. Pályi-Krekk Z, Barok M, Kovacs T, et al. EGFR and ErbB2 are functionally coupled to CD44 and regulate shedding, internalization and motogenic effect of CD44. Cancer Lett. 2008;263(2):231-242.
33. Meran S, Luo DD, Simpson R, et al. Hyaluronan facilitates transforming growth factor-beta1-dependent proliferation via CD44 and epidermal growth factor receptor interaction. J Biol Chem. 2011;286(20):17618-17630.
34. Olaku V, Matzke A, Mitchell C, et al. c-Met recruits ICAM-1 as a coreceptor to compensate for the loss of CD44 in Cd44 null mice. Mol Biol Cell. 2011;22(15):2777-2786.
35. Francavilla C, Loeffler S, Piccini D, et al. Neural cell adhesion molecule regulates the cellular response to fibroblast growth factor. J Cell Sci. 2007;120(Pt 24):4388-4394.
36. Whitaker GB, Limberg BJ, Rosenbaum JS. Vascular endothelial growth factor receptor-2 and neuropilin-1 form a receptor complex that is responsible for the differential signaling potency of VEGF(165) and VEGF(121). J Biol Chem. 2001;276(27):25520-25531.
37. Favier B, Alam A, Barron P, et al. Neuropilin-2 interacts with VEGFR-2 and VEGFR-3 and promotes human endothelial cell survival and migration. Blood. 2006;108(4):1243-1250. (Pubitemid 44232021)
38. Voltz JW, Brush M, Sikes S, et al. Phosphorylation of PDZ1 domain attenuates NHERF-1 binding to cellular targets. J Biol Chem. 2007;282(46):33879-33887. (Pubitemid 350159561)
39. Sawano A, Iwai S, Sakurai Y, et al. Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocytemacrophages in humans. Blood. 2001;97(3):785-791. (Pubitemid 32113414)
40. Waltenberger J, Claesson-Welsh L, Siegbah A, et al. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem. 1994;269(43):26988-26995. (Pubitemid 24332901)
41. Harhouri K, Kebir A, Guillet B, et al. Soluble CD146 displays angiogenic properties and promotes neovascularization in experimental hindlimb ischemia. Blood. 2010;115(18):3843-3851.
42. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370(9605):2103-2111. (Pubitemid 350296300)
43. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733-4740.
44. Van Meter ME, Kim ES. Bevacizumab: current updates in treatment. Curr Opin Oncol. 2010;22(6):586-591.
45. Van Cutsem E, Vervenne WL, Bennouna J, et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol. 2009;27(13):2231-2237.
46. Allegra CJ, Yothers G, O'Connell MJ, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol. 2011;29(1):11-16.
47. Adachi K, Hattori M, Kato H, et al. Involvement of gicerin, a cell adhesion molecule, in the portal metastasis of rat colorectal adenocarcinoma cells. Oncol Rep. 2010;24(6):1427-1431.
48. Aldovini D, Demichelis F, Doglioni C, et al. M-CAM expression as marker of poor prognosis in epithelial ovarian cancer. Int J Cancer. 2006;119(8):1920-1926. (Pubitemid 44356852)